Log in using OpenID

Tissue Plasminogen Activator Market

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots.
Tissue Plasminogen Activator Market - Size, Share,
Outlook, and Opportunity Analysis, 2018 – 2026
Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of
blood clots. It is a serine protease present in endothelial cells. With the help of serine protease,
the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for
clot disintegration.
Request Sample Copy of Research Report @
tPA is also be produced by using recombinant technology techniques known as recombinant
tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase.
These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a
drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the
Global Tissue Plasminogen Activator Market: Drivers
Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the
treatment of acute ischemic stroke. Increasing incidences of stroke has boosted the tissue
plasminogen activator market size. According to John Hopkins Medicines (JHM) in the U.S.,
around 795,000 people in the U.S. suffer from stroke per year, as reported in 2014. According
to the World Health Organization (WHO), stroke is the second leading cause of death and the
third leading cause of disability, worldwide, as reported in 2012. This is one of the major
factors driving the tissue plasminogen activator market growth.
Increasing prevalence of stroke incidences in growing geriatric population is another major
factor driving the market size. As per the Public Health England (PHE), around 38% of people
suffering from strokes were aged 40 to 69 in 2018. Moreover, tissue plasminogen activator
market revenue is witnessing further increase due to awareness about stroke and its symptoms.
In 2015, the Centers of Disease Control and Prevention (CDC) stated that around 38% of people
were able to recognize the major symptoms of stroke and were treated at the right time.
Global Tissue Plasminogen Activator Market: Restraints
The side effects such as nausea, vomiting, dizziness, and fever, of the drug is one of the factors
hindering tissue plasminogen activator market growth. Major side effects include hypertension,
intracranial hemorrhage, systemic hemorrhage, angioedema, and others. tPA also causes
complications of left ventricle. In 2011, the National Center for Biotechnology Information
recorded around 2% to 5% of patients with acute ischemic stroke receive rtPA in the U.S. In
2015, CDC reported around 140,000 deaths due to unavailability and adverse effects of tPA in
the U.S.
Moreover, tissue plasminogen activator market growth can also be hampered by substitute
product approvals by the Food and Drug Administration (FDA). For instance, after the approval
of stent retriever by FDA, in 2012, the global tissue plasminogen activator market growth was
affected, since tPA is not effective for major blood clots in comparison to the stent retriever
Report includes chapters which deeply display the following deliverable about industry :
• Tissue Plasminogen Activator Market Research Objective and Assumption
• Tissue Plasminogen Activator Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Tissue Plasminogen Activator Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Tissue Plasminogen Activator Market, By Regions
• Tissue Plasminogen Activator Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Tissue Plasminogen Activator Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Tissue Plasminogen Activator Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Tissue Plasminogen Activator Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Tissue Plasminogen Activator Market: Regional Analysis
North America is the leader in the global tissue plasminogen activator market, owing to rising
awareness about stroke and huge spending on treatment of stroke. For instance, in 2017, the
American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the U.S. every
year, which includes medicines for the treatment of stroke and cost of health care services.
Inquire Here Before Purchase of Research Report @
Asia pacific is the fastest growing region in the tissue plasminogen activator market, owing to
increasing demand drug coupled with rising stroke incidences in the region. According to WHO,
Indonesia, Philippines, China, and India have highest rates of stroke, which is 186.3, 134.7,
128, and 71.5, respectively, as recorded in 2017.
Global Tissue Plasminogen Activator Market: Competitive Landscape
Key players operating in the global tissue plasminogen activator market include Bayer AG,
Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich,
Taj Pharmaceuticals, and Cadila Healthcare Ltd.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Alex Huge
Alex Huge414   documents Email
Health and Medicine
File Size
124 KB
market, tissue plasminogen activator market
Report inappropriate content